ACIP recommends new interval between PCV13, PPSV23 vaccines for older adults

CDC's Advisory Committee on Immunization Practices (ACIP) is recommending that for immunocompetent adults aged 65 years and older who have not previously received pneumococcal vaccine, a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) should be given 1 year or more after a dose of 13-valent pneumococcal conjugate vaccine (PCV13).

CDC's Advisory Committee on Immunization Practices (ACIP) is recommending that for immunocompetent adults aged 65 years and older who have not previously received pneumococcal vaccine, a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) should be given 1 year or more after a dose of 13-valent pneumococcal conjugate vaccine (PCV13). The two vaccines should not be coadministered, ACIP said. But if a dose of PPSV23 is given earlier than the recommended interval, the dose does not have to be repeated. The interval for this group was increased from 6–12 month to at least 1 year; however, recommended intervals for all other age and risk groups have not changed. ACIP noted that studies of PCV–PPSV23 sequence among immunocompetent adults suggest shorter intervals may be associated with greater local reactogenicity compared with longer intervals, and longer intervals may lead to an increased immune response against serotypes in both vaccines compared with a single dose of PCV13 or PPSV23.